Astria Therapeutics

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Earnings data Q1 2023

Earnings data Q2 2023

Astria Therapeutics, Inc. (NASDAQ:ATXS ) Q4 2022 Earnings Conference Call March 22, 2023 8:30 AM ET Company Participants Andrea Matthews - Senior Vice President, Corporate Affairs Jill Milne - Chief Executive Officer Andy Nichols - Chief Scientific Officer Andrew Komjathy - Chief Commercial Officer Chris Morabito - Chief Medical Officer Noah Clauser - Chief Financial Officer Conference Call Participants Hartaj Singh - Oppenheimer Oliver McCammon - LifeSci Capital, LLC Joe Pantginis - H.C. Wainwright Eun Yang - Jefferies Michael Higgins - Ladenburg Thalmann Operator Good morning and welcome to the Astria Therapeutics 2022 Q4 and Full Year Financial Results and Business Update Conference Call.

Astria Therapeutics, Inc. (ATXS) Q4 2022 Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

Astria Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS) a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, will report fourth quarter/full year 2022 financial results before the Nasdaq Global Market open on Wednesday, March 22, 2023. Jill C. Milne, Ph.D.

Astria Therapeutics to Report Fourth Quarter/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the upcoming virtual Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13th at 1:20pm ET.

Astria Therapeutics to Present at Upcoming Oppenheimer 33rd Annual Healthcare Conference

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 10,000 shares of Astria's common stock on March 1, 2023 under Astria's 2022 Inducement Stock Incentive Plan.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc.

Astria Therapeutics Presents Additional Data Supporting STAR-0215 Profile as a Long-Acting Preventative Therapy for Hereditary Angioedema at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will share new STAR-0215 data in two poster presentations at the upcoming American Academy of Allergy, Asthma, and Immunology Annual Meeting in San Antonio, Texas on February 26, 2023 at 9:45am CST. Chris Morabito, M.D.

Astria Therapeutics to Present New STAR-0215 Data at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced the initiation of the ALPHA-STAR Phase 1b/2 clinical trial of STAR-0215 in people living with HAE. Initial proof-of-concept results in HAE patients from single and multiple dose cohorts are expected in mid-2024.

Astria Therapeutics Initiates ALPHA-STAR Phase 1b/2 Clinical Trial of STAR-0215 in People with HAE

The average of price targets set by Wall Street analysts indicates a potential upside of 70.1% in Astria Therapeutics, Inc. (ATXS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Astria Therapeutics, Inc. (ATXS) Have the Potential to Rally 70% as Wall Street Analysts Expect?

If you are looking for stocks that are well positioned to maintain their recent uptrend, Astria Therapeutics, Inc. (ATXS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

What Makes Astria Therapeutics, Inc. (ATXS) a Good Fit for 'Trend Investing'

ATXS has broken out from a 37-week price reversal. Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of swelling in various parts of the body.

Astria Therapeutics: Tailwinds Building With Novel Treatment Paradigm

BOSTON--( BUSINESS WIRE )--Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the “Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced the closing of its previously announced underwritten offering of 10,445,050 shares of its common stock, including the full exercise of the underwriters' option to purchase 1,362,397 shares of common stock, at a price of $11.01 per share. The gross proceeds of the offering were approximately $115 million, before deducting underwriting discounts and commissions and other offering expenses. All shares in the offering were offered by the Company.

Astria Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

BOSTON--( BUSINESS WIRE )--Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the “Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced the pricing of an underwritten offering of 9,082,653 shares of its common stock at a price of $11.01 per share. The gross proceeds of the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, the underwriters have a 30-day option to purchase up to an additional 1,362,397 shares of common stock at the public offering price less underwriting discounts and commissions.

Astria Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

BOSTON--( BUSINESS WIRE )--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced positive preliminary results from the Phase 1a clinical trial of STAR-0215 in healthy subjects establishing early proof of concept of STAR-0215 as a potential long-acting preventative treatment for HAE. STAR-0215 was well-tolerated at all doses studied. The results showed rapid and sustained drug levels consistent with clinical benefit and sustained target engagement with plasma kallikrein inhibition for at least three months, supporting the potential for STAR-0215 to be dosed once every three months or less frequently. Astria plans to initiate the ALPHA-STAR Phase 1b/2 trial in HAE patients in Q1 2023.

Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects

BOSTON--( BUSINESS WIRE )--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Astria Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that it will share preclinical data for STAR-0215 in a presentation titled “Modeling and Simulation Predicts Robust HAE Attack Suppression with Every Three Month Dosing of STAR-0215” at the 2022 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Louisville, Kentucky.

Astria Therapeutics to Present STAR-0215 Modeling and Simulation Data at the 2022 American College of Allergy, Asthma and Immunology Annual Meeting

Akero Therapeutics Inc

HeartBeam

ContraFect

Humanigen

Otonomy

Rhythm Pharmaceuticals

Vigil Neuroscience

Virios Therapeutics

The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.

These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that the Company will host a virtual R&D Day titled “Update on STAR-0215 and Its Clinical Development for the Prevention of HAE Attacks” on September 30th from 10:30am to 12:00pm ET. The event will feature a presentation by Dr. Marc Ried

Astria Therapeutics to Host Virtual R&D Day: Update on STAR-0215 and Its Clinical Development

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that the Company will be presenting at two upcoming investment conferences: H.C. Wainwright 24th Annual Global Investment Conference: Jill C. Milne, Ph.D., Chief Executive Officer at Astria will present a corporate overview and provide information

Astria Therapeutics to Present at Upcoming Investment Conferences

The mean of analysts' price targets for Astria Therapeutics, Inc. (ATXS) points to a 234.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Astria Therapeutics, Inc. (ATXS) Have the Potential to Rally 234% as Wall Street Analysts Expect?

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update. “We are thrilled to announce that we have initiated dosing in our Phase 1a trial of STAR-0215 which will provide data that we believe will validate

Astria Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced initiation of a Phase 1a clinical trial of STAR-0215 in healthy subjects. STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting, effective attack prevention for hereditary angioedema (HAE), with dosing o

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the upcoming virtual Wedbush PacGrow Healthcare Conference on Wednesday, August 10, at 9:10am ET. A webcast

Astria Therapeutics to Present at Upcoming Wedbush PacGrow Healthcare Conference 2022

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced the U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for STAR-0215, which the company is developing for the treatment of Hereditary Angioedema (HAE). A Phase 1a trial of STAR-0215 in healthy volun

Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema

News for Astria Therapeutics Stock (ATXS)